State Street’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-27,245
| Closed | -$8.99K | – | 4787 |
|
|
2023
Q1 | $8.99K | Hold |
27,245
| – | – | ﹤0.01% | 4750 |
|
|
2022
Q4 | $19.6K | Hold |
27,245
| – | – | ﹤0.01% | 4730 |
|
|
2022
Q3 | $33K | Hold |
27,245
| – | – | ﹤0.01% | 4747 |
|
|
2022
Q2 | $32K | Hold |
27,245
| – | – | ﹤0.01% | 4809 |
|
|
2022
Q1 | $59K | Hold |
27,245
| – | – | ﹤0.01% | 4768 |
|
|
2021
Q4 | $41K | Hold |
27,245
| – | – | ﹤0.01% | 4730 |
|
|
2021
Q3 | $80K | Hold |
27,245
| – | – | ﹤0.01% | 4592 |
|
|
2021
Q2 | $90K | Buy |
+27,245
| New | +$87.4K | ﹤0.01% | 4381 |
|
|
2020
Q1 | – | Sell |
-1,910
| Closed | -$25K | – | 3802 |
|
|
2019
Q4 | $25K | Sell |
1,910
-3,644
| -66% | -$33.6K | ﹤0.01% | 3758 |
|
|
2019
Q3 | $58K | Buy |
5,554
+145
| +3% | +$1.9K | ﹤0.01% | 3709 |
|
|
2019
Q2 | $92K | Sell |
5,409
-67,023
| -93% | -$1.81M | ﹤0.01% | 3675 |
|
|
2019
Q1 | $2.44M | Buy |
72,432
+3,191
| +5% | +$107K | ﹤0.01% | 3069 |
|
|
2018
Q4 | $2.02M | Sell |
69,241
-403
| -0.6% | -$17.9K | ﹤0.01% | 3114 |
|
|
2018
Q3 | $4.29M | Buy |
69,644
+4,873
| +8% | +$330K | ﹤0.01% | 2924 |
|
|
2018
Q2 | $4.78M | Buy |
64,771
+19,738
| +44% | +$1.54M | ﹤0.01% | 2880 |
|
|
2018
Q1 | $2.96M | Buy |
45,033
+1,205
| +3% | +$91K | ﹤0.01% | 3015 |
|
|
2017
Q4 | $3.69M | Buy |
43,828
+782
| +2% | +$76.7K | ﹤0.01% | 2928 |
|
|
2017
Q3 | $4.97M | Buy |
43,046
+1,349
| +3% | +$142K | ﹤0.01% | 2804 |
|
|
2017
Q2 | $4.87M | Buy |
41,697
+5,932
| +17% | +$736K | ﹤0.01% | 2744 |
|
|
2017
Q1 | $4.42M | Buy |
35,765
+3,161
| +10% | +$414K | ﹤0.01% | 2770 |
|
|
2016
Q4 | $4.44M | Buy |
32,604
+1,514
| +5% | +$269K | ﹤0.01% | 2756 |
|
|
2016
Q3 | $6.19M | Buy |
31,090
+2,710
| +10% | +$467K | ﹤0.01% | 2441 |
|
|
2016
Q2 | $3.68M | Buy |
28,380
+17,140
| +152% | +$1.91M | ﹤0.01% | 2777 |
|
|
2016
Q1 | $1.05M | Buy |
11,240
+1,068
| +10% | +$116K | ﹤0.01% | 3203 |
|
|
2015
Q4 | $2.06M | Buy |
10,172
+1,898
| +23% | +$340K | ﹤0.01% | 2987 |
|
|
2015
Q3 | $1.2M | Buy |
8,274
+383
| +5% | +$70.3K | ﹤0.01% | 3169 |
|
|
2015
Q2 | $1.68M | Buy |
7,891
+3,122
| +65% | +$765K | ﹤0.01% | 3120 |
|
|
2015
Q1 | $1.11M | Buy |
+4,769
| New | +$1.15M | ﹤0.01% | 3212 |
|
Other funds holding BLCM
BC
BRWA
TCM
PGAM
State Street's BLCM Position: Q2 2023 in Review
State Street sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 27,245 shares — an estimated $8.99K sold.
State Street first reported a position in BLCM in Q1 2015 and held it in 28 quarters. The position peaked at $6.19M in Q3 2016. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.
- State Street reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
- State Street sold 27,245 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $8.99K.
- State Street first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 28 quarters.
- State Street's Bellicum Pharmaceuticals, Inc. position peaked at $6.19M in Q3 2016.
- 4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.
Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.